Berkshire Sells DaVita Shares at $180.43, Retains 28.31M Shares

The disclosure matters less for its size than for what it leaves unsaid: without the share count or proceeds, the market can only judge the direction of travel, not its scale, and Berkshire's remaining 28.31 million shares keep it a dominant holder regardless. DaVita is a dialysis operator whose valuation has long been tied to reimbursement policy and leverage, so any sustained reduction by its largest backer draws attention to how concentrated that ownership still is. What's worth watching is whether further filings reveal the pace of any continued selling.